Cryofocus Medtech (Shanghai) Co., Ltd. filed its Monthly Return for Equity Issuers to the Hong Kong Stock Exchange for the period ended 31 August 2026, confirming a steady capital structure with no share movements during the month.

The company’s registered share capital stood at RMB 244.71 million, unchanged from July. This comprises: • 149.03 million H shares listed on the Hong Kong Stock Exchange, each with a par value of RMB 1. • 95.67 million unlisted domestic shares, also at RMB 1 par value.

Issued share capital mirrored the registered totals, with 149.03 million H shares and 95.67 million unlisted shares outstanding. The firm reported zero treasury shares and no issuance, cancellation, or repurchase activity in August.

Cryofocus Medtech confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent for its H-share class. The company also reported no outstanding share options, warrants, convertible securities, or other equity-linked instruments.

Director Zhu Jun submitted the return on 2 September 2026, underscoring management’s commitment to transparency amid stable capital metrics.